The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Open accessAbstract
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selective activation of the immune system, immune-related adverse events (irAEs) are frequent. Enterocolitis is a common irAE, currently managed with corticosteroids and, if necessary, anti-tumor necrosis factor-α therapy. Such a regimen carries a risk of serious side-effects including infections, and may potentially imply impaired antitumor effects. Vedolizumab is an anti-integrin α4β7 antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and ulcerative colitis. We report a case series of seven patients with metastatic melanoma or lung cancer, treated with vedolizumab off-label for ipilimumab- or nivolumab-induced enterocolitis, from June 2014 through October 2016. Clinical, laboratory, endoscopic, and histologic data were analyzed. Patients initially received corticosteroids but were steroid-dependent and/or partially refractory. One patient was administered infliximab but was refractory. The median time from onset of enterocolitis to start of vedolizumab therapy was 79 days. Following vedolizumab therapy, all patients but one experienced steroid-free enterocolitis remission, with normalized fecal calprotectin. This was achieved after a median of 56 days from vedolizumab start, without any vedolizumab-related side-effects noted. The patient in whom vedolizumab was not successful, due to active ulcerative colitis, received vedolizumab prophylactically. This is the first case series to suggest that vedolizumab is an effective and well-tolerated therapeutic for steroid-dependent or partially refractory ICPI-induced enterocolitis. A larger prospective study to evaluate vedolizumab in this indication is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on two retrospective series, VDZ is an effective and well-tolerated therapeutic for steroid-dependent or refractory ICI-induced enterocolitis.69,70”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F., Aneja, P., Ocaña, A., Leibowitz‐Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 3,304
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P. J., Hanauer, S. B., Colombel, J., Sands, B. E., Lukáš, M., Fedorak, R. N., Lee, S., Bressler, B. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,716
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I. E., Matteson, E. L., & Montori, V. M. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,470
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Daperno, M., D’Haens, G., Assche, G. V., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,779
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1
Berlin, C., Berg, E. L., Briskin, M. J., Andrew, D. P., Kilshaw, P. J., Holzmann, B., Weissman, I. L., Hamann, A., & Butcher, E. C. (1993) · Cell · doi:10.1016/0092-8674(93)90305-a · Cited by 1,453
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Törüner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,027
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J., Sands, B. E., Rutgeerts, P. J., Sandborn, W. J., Danese, S., D’Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I. H., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 805
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
Langhorst, J., Elsenbruch, S., Koelzer, J., Rueffer, A., Michalsen, A., & Dobos, G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01556.x · Cited by 588
Wolfe, F., & Michaud, K. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 537
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Long, M. D., Martin, C. F., Pipkin, C. A., Herfarth, H. H., Sandler, R. S., & Kappelman, M. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.004 · Cited by 531
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 485
Soler, D. F., Chapman, T. R., Yang, L.-L., Wyant, T. L., Egan, R. W., & Fedyk, E. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153973 · Cited by 457
Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity
Travis, S. P. L., Schnell, D. J., Krzeski, P., Abreu, M. T., Altman, D. G., Colombel, J., Feagan, B. G., Hanauer, S. B., Lichtenstein, G. R., Marteau, P. R., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.024 · Cited by 456
Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy
von Roon, A. C., Karamountzos, L., Purkayastha, S., Reese, G., Darzi, A. W., TEARE, J. P., Paraskeva, P. A., & Tekkis, P. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01126.x · Cited by 403
Xavier Mariette, A., Matucci‐Cerinic, M., Pavelká, K., Taylor, P. C., van Vollenhoven, R., Heatley, R., Walsh, C., Lawson, R., Reynolds, A., & Emery, P. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.149419 · Cited by 403
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin, A. D., Wildenberg, M. E., & BRINK, G. R. V. D. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw053 · Cited by 338
Castillo, M. D., Romero, F. A. R., Argüello, E., Kyi, C., Postow, M. A., & Redelman‐Sidi, G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw539 · Cited by 292
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Wyant, T. L., Fedyk, E. R., & Abhyankar, B. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw092 · Cited by 284
Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
Callahan, M. K., Wolchok, J. D., & Allison, J. P. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.001 · Cited by 248
Kawaguchi, T., Azuma, K., Sano, M., Kim, S., Kawahara, Y., Sano, Y., Shimodaira, T., Ishibashi, K., Miyaji, T., Basch, E., et al. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-017-0022-5 · Cited by 248
Raaschou, P., Simard, J. F., Holmqvist, M. E., Askling, J., & for the ARTIS Study Group (2013) · BMJ · doi:10.1136/bmj.f1939 · Cited by 213
Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease
Marehbian, J., Arrighi, H. M., Hass, S., Tian, H., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.322 · Cited by 208
Feng, Y., Roy, A., Masson, E., Chen, T., Humphrey, R. W., & Weber, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3243 · Cited by 187
Tissue-Specific Actions of Glucocorticoids on Apoptosis: A Double-Edged Sword
Gruver-Yates, A., & Cidlowski, J. A. (2013) · Cells · doi:10.3390/cells2020202 · Cited by 146
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
Verschuren, E. C., van den Eertwegh, A. J. M., Wonders, J., Slangen, R. M. E., van Delft, F., Bodegraven, A. A. V., Neefjes‐Borst, A., & de Boer, N. K. H. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.12.028 · Cited by 144
Ipilimumab-induced acute severe colitis treated by infliximab
Pagès, C., Gornet, J. M., Monsel, G., Allez, M., Bertheau, P., Bagot, M., Lebbé, C., & Viguier, M. A. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835fb524 · Cited by 127
Opportunistic infections in patients treated with immunotherapy for cancer
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-19 · Cited by 119
Emerging role of calprotectin in gastroenterology
Poullis, A. P., Foster, F., Mendall, M. A., & Fagerhol, M. K. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03014.x · Cited by 118
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
Lord, J. D., Hackman, R. C., Moklebust, A., Thompson, J. A., Higano, C. S., Chielens, D., Steinbach, G., & McDonald, G. B. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0839-8 · Cited by 95
Travis, S. P. L., Schnell, D. J., Feagan, B. G., Abreu, M. T., Altman, D. G., Hanauer, S. B., Krzeski, P., Lichtenstein, G. R., Marteau, P. R., Mary, J., et al. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv077 · Cited by 59
Vedolizumab: a novel treatment for ipilimumab-induced colitis
Hsieh, A. H., Ferman, M., Brown, M. P., & Andrews, J. M. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216641 · Cited by 58
Introducing Vedolizumab to Clinical Practice: Who, When, and How?
Bryant, R. V., Sandborn, W., & Travis, S. P. L. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv033 · Cited by 56
Infliximab for IPILIMUMAB-Related Colitis—Letter
Arriola, E., Wheater, M. J., Karydis, I., Thomas, G. J., & Ottensmeier, C. H. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2471 · Cited by 53
Ipilimumab-induced colitis in patients with metastatic melanoma
Felice, K. M. D., Gupta, A., Rakshit, S., Khanna, S., Kottschade, L. A., Finnes, H. D., Papadakis, K. A., Loftus, E. V., Raffals, L. E., & Markovic, S. N. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000165 · Cited by 48
Arriola, E., Wheater, M. J., Krishnan, R., Smart, J., Foria, V., & Ottensmeier, C. H. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1040218 · Cited by 45
The cost of ipilimumab toxicity
Yousaf, N., Davidson, M., Goode, E., Thomas, C., Hung, R. K. Y., Gore, M. E., & Larkin, J. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000158 · Cited by 23
Weighing Up the Pros and Cons of Immune Checkpoint Inhibitors in The Treatment of Melanoma
Spain, L. A., & Larkin, J. (2016) · Immunotherapy · doi:10.2217/imt.16.6 · Cited by 9
Flagged first, then by citations
Cited by
Sorted by citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,498
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
“This preliminary study suggests that vedolizumab is an alternative to infliximab [43].”
BackgroundImmune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
Metadata
- Authors
- Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J.
- Affiliations
- Skåne University Hospital (SE)
- Lund University (SE)
- Corresponding author
- Marsal, Jan
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2017-02-15
- Volume
- 66
- Issue
- 5
- Pages
- 581-592
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC5406433
- OpenAlex
- W2588366403
- Cited by
- 234
- References
- 56
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 20 · 2023: 13 · 2022: 24 · 2021: 33 · 2020: 41 · 2019: 37 · 2018: 35 · 2017: 6
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Hedlund Foundation
- Alfred Österlunds Stiftelse
- Julin Foundation
- Kungliga Fysiografiska Sällskapet i Lund
- Svenska Läkaresällskapet
- Grants to researchers in the public health care from the Swedish government (ALFSKANE-539811)
- Healthcare Region of Southern Sweden
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- vedolizumab, immune-related adverse events, ipilimumab, nivolumab, pembrolizumab, CTLA-4, PD-1, metastatic melanoma, lung cancer, off-label drug use, fecal calprotectin, ulcerative colitis
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Enterocolitis, Female, Gastrointestinal Agents, Humans, Lung Neoplasms, Male, Melanoma, Middle Aged, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
